Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Neural Therapeutics Inc. ( (TSE:NURL) ) has provided an announcement.
Neural Therapeutics Inc. has filed a patent application for the treatment of major mental health conditions using mescaline and a novel extraction technology for pharmaceutical-grade mescaline products. This development positions Neural as a leader in the mescaline space, focusing on sub-hallucinogenic doses to provide therapeutic benefits without the side effects associated with higher doses. The company also announced a ticker symbol change on the Frankfurt Stock Exchange to ‘HANF’ and extended a letter of intent with CWE European Holdings, indicating ongoing strategic partnerships and growth opportunities.
More about Neural Therapeutics Inc.
Neural Therapeutics Inc. is an ethnobotanical drug discovery company that focuses on developing therapeutic drugs for mental illnesses related to substance use disorders, including alcohol and opioid dependence. The company employs innovative approaches such as the use of sub-hallucinogenic doses of mescaline extract to enhance safety and scalability while maintaining therapeutic efficacy.
Average Trading Volume: 83,827
See more insights into NURL stock on TipRanks’ Stock Analysis page.